Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InnoCare Pharma Ltd. ( (HK:9969) ) has shared an update.
InnoCare Pharma has granted 15,389,245 restricted share units under its 2023 Share Award Scheme to three grantees, including executive directors Dr. Cui and Dr. Zhao and a senior manager, representing about 0.87% of its issued share capital. The RSUs, priced at nil with a reference share price of HK$14.7 on the grant date, will vest in four equal tranches over four years, subject to shareholder approval for awards to relevant executive directors.
The vesting of the RSUs is tied to performance targets at both corporate and individual levels, linking compensation to operating revenue milestones, the number of clinical trials and assessments of individual performance. The move reinforces InnoCare Pharma’s long-term incentive framework, aligning management interests with shareholders and signaling a focus on commercialization progress and R&D execution in the coming years.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$18.31 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong that focuses on the research, development and commercialization of innovative therapies. The company operates in the pharmaceutical industry with a strong emphasis on R&D and clinical trials to advance its drug pipeline and support long-term growth in key therapeutic areas.
Average Trading Volume: 8,414,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$21.04B
For detailed information about 9969 stock, go to TipRanks’ Stock Analysis page.